Breaking News
Get 40% Off 0
🎁 Free Gift Friday: Copy Legendary Investors' Portfolios in One Click Copy for Free
Close

Provention Bio Inc (PRVB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Provention Bio's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Provention Bio historical data, for real-time data please try another search
24.980 +0.000    +0.00%
26/04 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 24.980 - 25.000
Provention Bio 24.980 +0.000 +0.00%

PRVB Balance Sheet

 
Featured here, the Balance Sheet for Provention Bio Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2022
31/12
2022
30/09
2022
30/06
2022
31/03
Total Current Assets 174.65 190.43 90.3 91.79
Cash and Short Term Investments 165 185.52 84.52 85.04
Cash - - - -
Cash & Equivalents 44.04 102.38 57.88 74.91
Short Term Investments 120.96 83.14 26.64 10.13
Total Receivables, Net 1.36 - - -
Accounts Receivables - Trade, Net 1.36 - - -
Total Inventory 1.23 - - -
Prepaid Expenses 7.06 4.91 5.78 6.74
Other Current Assets, Total - - - -
Total Assets 236.86 193.91 104.35 122.46
Property/Plant/Equipment, Total - Net 2.53 2.35 2.31 2.24
Property/Plant/Equipment, Total - Gross 3.55 3.19 3.01 2.79
Accumulated Depreciation, Total -1.02 -0.837 -0.693 -0.557
Goodwill, Net - - - -
Intangibles, Net 59.56 - - -
Long Term Investments - 1.01 11.61 28.32
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 0.12 0.12 0.12 0.12
Other Assets, Total 120.84 83.14 26.64 10.13
Total Current Liabilities 90.39 25.12 25.15 27.05
Accounts Payable 51.95 3.79 5.66 7.24
Payable/Accrued - - - -
Accrued Expenses 20.6 13.41 12.08 12.3
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 0.151 0.144 0.138 0.131
Other Current liabilities, Total 17.69 7.78 7.28 7.37
Total Liabilities 115.01 49.14 25.67 28.25
Total Long Term Debt 23.47 23.3 - -
Long Term Debt 23.47 23.3 - -
Capital Lease Obligations - - - -
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total -22.32 -22.57 0.518 1.21
Total Equity 121.85 144.77 78.68 94.21
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 0.009 0.009 0.007 0.006
Additional Paid-In Capital 528.13 518.01 423.24 408.96
Retained Earnings (Accumulated Deficit) -405.64 -372.36 -343.73 -314.04
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -0.647 -0.886 -0.841 -0.714
Total Liabilities & Shareholders' Equity 236.86 193.91 104.35 122.46
Total Common Shares Outstanding 87.67 87.05 66.43 63.76
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PRVB Comments

Write your thoughts about Provention Bio Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
zoltán csorba
zoltán csorba Mar 13, 2023 11:21PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
go 10$
John Berry
John Berry Mar 13, 2023 4:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Easy 300% winner
Mavi Yesil
Mavi Yesil Feb 13, 2023 12:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think they will produce insulin as pills
Mavi Yesil
Mavi Yesil Feb 13, 2023 12:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The convenience foods we consume make us suffer from diabetes. Diabetes is also common in children under the age of 10. Sugar is the disease of humanity. Everyone around me uses insulin. Medicines for diabetes are humanity's greatest hope. This company will do great things. drug production is great. It gives hope and expectation.
John Avenetti
John Avenetti Aug 05, 2021 1:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
earnings? they're in clinical trials.
Tim Crum
Tim Crum May 27, 2021 5:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
going to pop tomorrow
John Avenetti
John Avenetti May 27, 2021 5:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it seems likely
Tim Crum
Tim Crum May 27, 2021 5:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why is premarket down? doesn't make sense. I see this as likely being approved as long as the PK data with FDA gets sorted out.
Szoka Krisztian
Szoka Krisztian May 25, 2021 2:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://finance.yahoo.com/news/prvb-shareholder-alert-bronstein-gewirtz-140000371.html
Sean ONeal
Sean ONeal Mar 11, 2021 6:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
interesting info https://www.jdrf.org/blog/2020/06/15/updates-teplizumab-trial-going-believe-results/
Tom Daniel
Tom Daniel Mar 11, 2021 6:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
stock price doesn't GAF
Sky Emperor
SkyEmperor Dec 10, 2020 10:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Finally some movements
Sky Emperor
SkyEmperor Nov 19, 2020 8:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
So i expected yesterday to have some impact the presentation,now what happened anyone knows? No big changes, still in range of 15
Gene Emory
Gene Emory Nov 19, 2020 8:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hold till news of fda approval. I see $100 by end of 2021. Happy trading...
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email